BridgeBio Pharma

Our CMO of Skeletal Dysplasias, Daniela Rogoff, M.D., Ph.D., was featured in @RareRevolutionM as part of Women in RARE, highlighting her career in #raredisease drug development and her commitment to making a meaningful difference for patients and families. We're grateful to have leaders like Daniela at BridgeBio who bring passion, scientific expertise and a patient-first perspective to everything they do. Read the full feature: rarerevolutionmagazine.com/rare-insider/d…

How can regulation keep pace with medical innovation?
Our Chief Regulatory Affairs Officer will join fellow panelists at the @MilkenInstitute #MIHealth Summit to explore evolving regulatory approaches, emerging technologies and global alignment. We look forward to Adora lending her expertise to this important conversation.

Early diagnosis is critical in limb-girdle muscular dystrophy (LGMD). Timely subtype confirmation via genetic testing may help inform management and anticipate complications, including the cardiac and respiratory involvement seen in LGMD2I/R9.

Jen put her career on hold to care for her son Mason, who lives with ADH1. “It was an unexpected sacrifice, but…seeing him thrive has been the most important and deeply rewarding work of my life.” Read more about Jen's story in honor of #CaregiverAwarenessMonth: bit.ly/4sQP49Z

“There are so many kids and so many families who fought for this for so long. Generations.” – Lee and Lori Greenwood, parents to Noa. Noa is one of more than 30 million Americans living with a rare disease. Behind that number are families still waiting. Watch the full video on our Insights page: bit.ly/4z9U5fL